ENZON PHARMACEUTICALS, INC. 8-K

What Happened

• Enzon Pharmaceuticals (ENZN) announced on March 9, 2026 that it extended the expiration of its exchange offer to holders of its Series C Non-Convertible Redeemable Preferred Stock to exchange those shares for Enzon common stock. After the extension, the Offer now expires one minute after 11:59 p.m., Eastern Time, on March 11, 2026, unless further extended. The announcement was made via a press release attached as Exhibit 99.1 to the 8-K.
• The exchange offer and related materials are part of the broader proposed transaction between Enzon and Viskase Companies, Inc.; Enzon previously filed a registration statement on Form S-4 (which includes a prospectus, consent solicitation statement, and offer to exchange) with the SEC.

Key Details

• New Offer expiration: one minute after 11:59 p.m. ET on March 11, 2026 (unless extended further).
• Offer subject: Series C Non-Convertible Redeemable Preferred Stock exchanged for Enzon common stock.
• Related filing: Registration Statement on Form S-4 has been filed in connection with the proposed Enzon–Viskase transaction; the S-4 is available on SEC.gov and Enzon’s website.
• The 8-K disclosure includes forward‑looking statement cautions and notes the release is a Regulation FD disclosure (Exhibit 99.1).

Why It Matters

• For holders of Series C preferred shares, the extension provides additional time to decide whether to tender their preferred stock for Enzon common shares under the exchange offer.
• For investors tracking the proposed merger with Viskase, the extension affects the timeline for the exchange process and is tied to materials in the S-4 registration statement; the filing reiterates that the transaction remains subject to customary closing conditions and risks.
• This 8-K is a disclosure of the extension (Regulation FD) and not a substitute for the S-4/prospectus—investors should review the S-4 and related filings on SEC.gov for full details before making decisions.